These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 34439292)

  • 1. Pancreatic Cancer and Immunotherapy: A Clinical Overview.
    Timmer FEF; Geboers B; Nieuwenhuizen S; Dijkstra M; Schouten EAC; Puijk RS; de Vries JJJ; van den Tol MP; Bruynzeel AME; Streppel MM; Wilmink JW; van der Vliet HJ; Meijerink MR; Scheffer HJ; de Gruijl TD
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer.
    Ostios-Garcia L; Villamayor J; Garcia-Lorenzo E; Vinal D; Feliu J
    World J Gastroenterol; 2021 Oct; 27(40):6775-6793. PubMed ID: 34790007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future immunotherapeutic approaches in pancreatic cancer treatment.
    Farhangnia P; Khorramdelazad H; Nickho H; Delbandi AA
    J Hematol Oncol; 2024 Jun; 17(1):40. PubMed ID: 38835055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer.
    Wandmacher AM; Letsch A; Sebens S
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
    Ibrahim AM; Wang YH
    World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies.
    Guo S; Wang Z
    Front Oncol; 2024; 14():1349308. PubMed ID: 38590651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.
    Chouari T; La Costa FS; Merali N; Jessel MD; Sivakumar S; Annels N; Frampton AE
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapeutic approach for advanced pancreatic adenocarcinoma.
    Kaur J; Mir T; Gill R; Duong J; Marcus S; Khan R
    Immunotherapy; 2021 Jun; 13(9):767-782. PubMed ID: 33910383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?-A Comprehensive Review.
    Garnier J; Turrini O; Chretien AS; Olive D
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for the Treatment of Urothelial Carcinoma.
    Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
    J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic Strategies in Pancreatic Cancer: Making
    Ullman NA; Burchard PR; Dunne RF; Linehan DC
    J Clin Oncol; 2022 Aug; 40(24):2789-2805. PubMed ID: 35839445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.
    Young K; Hughes DJ; Cunningham D; Starling N
    Ther Adv Med Oncol; 2018; 10():1758835918816281. PubMed ID: 30574212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiating prostate cancer immunotherapy with oncolytic viruses.
    Lee P; Gujar S
    Nat Rev Urol; 2018 Apr; 15(4):235-250. PubMed ID: 29434366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.